$41.59
-0.25[-0.60%]
At close: Apr 26
$41.59
0[0.00%]
After Hours: 4:20PM EDT
Ionis Pharmaceuticals: Insider buying and selling updated today.
Filing Date | Insider Names | Insider Title | Qty. | Price | Size ($) | Type | Δ Own | Own | Trade Dates | SEC Filing |
---|---|---|---|---|---|---|---|---|---|---|
Apr 17, 2024 | Joseph Baroldi | EVP, CHIEF BUSINESS OFFICER | 6.832K | $41.60 | -$166.64K | SELL-OPTIONS | 47.32% | 21.271K | Apr 15 - Apr 16 | View |
Apr 17, 2024 | Brian Birchler | EVP, CORP AND DEVELOPMENT OPS | 970 | $41.66 | -$37.70K | SELL-OPTIONS | 2.15% | 46.156K | Apr 15 - Apr 16 | View |
Feb 16, 2024 | Brett P Monia | CHIEF EXECUTIVE OFFICER | -387 | $44.49 | -$17.22K | SELL | -0.22% | 173.751K | Feb 16 | View |
Feb 02, 2024 | Eric Swayze | EVP RESEARCH | -8.965K | $51.63 | -$654.71K | SELL | -20.67% | 34.409K | Jan 31 - Feb 02 | View |
Feb 02, 2024 | Eugene Schneider | EVP, CHF CLINICAL DEVELOP OFCR | 1.962K | $49.59 | -$102.70K | GRANT | 4.10% | 49.812K | Feb 01 - Feb 02 | View |
Feb 02, 2024 | Patrick R. O'Neil | EVP CLO & GENERAL COUNSEL | 1.859K | $49.67 | -$97.41K | GRANT | 3.97% | 48.661K | Feb 01 - Feb 02 | View |
Feb 02, 2024 | Brett P Monia | CHIEF EXECUTIVE OFFICER | 22.287K | $49.37 | -$1.16M | GRANT | 14.68% | 174.138K | Feb 01 - Feb 02 | View |
Feb 02, 2024 | Elizabeth L Hougen | EVP, FINANCE & CFO | 2.015K | $49.54 | -$105.27K | GRANT | 2.22% | 92.905K | Feb 01 - Feb 02 | View |
Feb 02, 2024 | Richard S Geary | EVP, CHIEF DEVELOPMENT OFFICER | 1.859K | $50.04 | -$98.13K | GRANT | 2.17% | 87.334K | Feb 01 - Feb 02 | View |
Feb 02, 2024 | Onaiza Cadoret-Manier | EVP, CHF GL PDT STR & OPER OFC | 2.015K | $49.60 | -$105.40K | GRANT | 5.96% | 35.825K | Feb 01 - Feb 02 | View |
Feb 02, 2024 | C. Frank Bennett | EVP, CHIEF SCIENTIFIC OFFICER | 1.756K | $49.52 | -$91.75K | GRANT | 2.27% | 79.079K | Feb 01 - Feb 02 | View |
Jan 29, 2024 | Brett P Monia | CHIEF EXECUTIVE OFFICER | -2.285K | $51.75 | -$118.25K | SELL | -1.48% | 151.851K | Jan 25 | View |
Jan 29, 2024 | Patrick R. O'Neil | EVP CLO & GENERAL COUNSEL | -6.45K | $51.75 | -$333.79K | SELL | -12.11% | 46.802K | Jan 25 | View |
Jan 18, 2024 | Onaiza Cadoret-Manier | EVP, CHF GL PDT STR & OPER OFC | 9.498K | $50.42 | -$280.52K | SELL-OPTIONS | 39.07% | 33.81K | Jan 16 - Jan 17 | View |
Jan 18, 2024 | Patrick R. O'Neil | EVP CLO & GENERAL COUNSEL | 12.897K | $50.42 | -$390.43K | SELL-OPTIONS | 31.96% | 53.252K | Jan 16 - Jan 17 | View |
Jan 18, 2024 | Brian Birchler | EVP, CORP AND DEVELOPMENT OPS | 7.583K | $50.42 | -$226.73K | SELL-OPTIONS | 20.50% | 44.582K | Jan 16 - Jan 17 | View |
Jan 18, 2024 | Eric Swayze | EVP RESEARCH | 10.785K | $50.42 | -$317.88K | SELL-OPTIONS | ∞ | 85 | Jan 16 - Jan 17 | View |
Jan 18, 2024 | Eugene Schneider | EVP, CHF CLINICAL DEVELOP OFCR | 9.68K | $50.42 | -$276.39K | SELL-OPTIONS | 25.36% | 47.85K | Jan 16 - Jan 17 | View |
Jan 18, 2024 | Brett P Monia | CHIEF EXECUTIVE OFFICER | 36.025K | $50.42 | -$1.62M | SELL-OPTIONS | 30.50% | 154.136K | Jan 16 - Jan 17 | View |
Browse insider trades on all stocks.